Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proposed Patent Reform Bill Would Codify Georgia-Pacific Factors

This article was originally published in The Gray Sheet

Executive Summary

Sen. Jon Kyl, R-Ariz., plans to soon introduce a patent damages bill that does not include the apportionment provisions opposed by the medical device industry and contained in legislation sponsored by Sen. Patrick Leahy (S. 1145)
Advertisement

Related Content

Senators Willing To Negotiate On Patent Reform Bill Damage Provisions
Senators Willing To Negotiate On Patent Reform Bill Damage Provisions
Senators Willing To Negotiate On Patent Reform Bill Damage Provisions
Kyl’s Patent Reform Bill Gains Acceptance From Device And Drug Industries
Kyl’s Patent Reform Bill Gains Acceptance From Device And Drug Industries
Biotech, Device Industries Team Up On Patent Reform
Biotech, Device Industries Team Up On Patent Reform
Patent Bill Damages Provision Still Up For Debate – Senate Committee Report
Patent reform passes House
Patent Reform Amendments Don’t Satisfy Opponents, But Mark-Up Continues
Advertisement
UsernamePublicRestriction

Register

MT026471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel